Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty...

